drugset / Trial / NCT01142050

Stem Cell Therapy for Type 2 Diabetes Mellitus

NCT01142050

Phase 1 Unknown 24 enrolled Cellonis Biotechnology Co. Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the efficacy and safety in the treatment of Insulin Resistance of Type 2 Diabetes Mellitus with Bone Marrow Mesenchymal Stem Cells.

Timeline

Start
2010-08
Primary completion
2011-08
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy Other